Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

G. Gebhart, L. E. Lamberts, Z. Wimana, C. Garcia, P. Emonts, L. Ameye, S. Stroobants, M. Huizing, P. Aftimos, J. Tol, W. J. G. Oyen, D. J. Vugts, O. S. Hoekstra, C. P. Schroder, C. W. Menke-van der Houven van Oordt, T. Guiot, A. H. Brouwers, A. Awada, E. G. E. de Vries, P. Flamen

Research output: Contribution to journalArticleAcademicpeer-review

241 Citations (Scopus)
Original languageEnglish
Pages (from-to)619-624
JournalAnnals of Oncology
Issue number4
Publication statusPublished - Apr 2016


  • HER2 imaging
  • HER2-positive breast cancer
  • prediction of T-DM1 efficacy

Cite this